# Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

> **NCT01422486** · PHASE2 · TERMINATED · sponsor: **Telik** · enrollment: 2 (actual)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** ezatiostat hydrochloride (Telintra®)

## Key facts

- **NCT ID:** NCT01422486
- **Lead sponsor:** Telik
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study TLK199.2107 was terminated for business reasons.
- **Last updated:** 2013-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01422486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01422486, "Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01422486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*